This section of the website is for patients who have been prescribed Somatuline® Autogel® (lanreotide) in Ireland. Information for members of the general public can be found here.
Side effects reporting information is available at the bottom of this webpage.

This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for an Irish audience

The decision to administer the injection by the patient or another trained person should be taken by a healthcare professional

All materials

OnCo on Air NETs – Episode 4 – Diet and NETs – What do I need to know?

Neuroendocrine Tumours (NETs) Video
22:00

In this podcast ‘Diet and NETs – What do I need to know?‘ episode, questions patient’s may have on modifying their diet while undergoing treatment for a NET are answered. Patients Tom O’Donoghue and Andrea Martin share how their diets have evolved following their diagnosis and treatment. Along with Dr Hussein Almeamar, they discuss the changes they’ve made to manage their symptoms and explore how other patients may benefit from tailoring their diet to their symptoms and treatment.

SOM-IE-000754 | November 2025

Explore more Neuroendocrine Tumours (NETs) Patient Support

Explore more Neuroendocrine Tumours (NETs) Patient Support

Browse

Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to the HPRA. Reporting forms and information can be found at www.hpra.ie or email medsafety@hpra.ie. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256. By reporting side effects, you can help provide more information on the safety of this medicine.

To access relevant information about Neuroendocrine Tumours (NETs), please choose one of the following options:

I am a Healthcare Professional in Ireland

This section of the website is for healthcare professionals in Ireland only and contains promotional content regarding our medicines

I am a Healthcare Professional in Ireland

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

I am a patient

This section provides information to support patients that have been prescribed Somatuline® Autogel® (lanreotide). It has been designed for Irish patients and should not replace the details contained in the Patient Information Leaflet.

I am a patient

I am a member of the general public

This section is for members of the general public.

I am a member of the general public

Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to the HPRA. Reporting forms and information can be found at www.hpra.ie or email medsafety@hpra.ie. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256. By reporting side effects, you can help provide more information on the safety of this medicine.